window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : November 16, 2025

  • News
  • About Us
Contact Us

Phesi

  • Chronic diseases,Data Management,Drug Development,Pharmaceuticals and therapeutics,Real world evidence,Research & Development

    New Phesi data shows more than 100 diseases being studied with GLP-1 therapies

    Analysis highlights potential for benefits far beyond obesity, signalling a [...]

    September 12, 2025
  • Clinical Development,Clinical Trials,Patient Centricity

    Phesi CEO warns of looming Phase 3 trial failures as sponsors overlook real-world data and overcrowd sites

    New analysis reveals billions risked on overly complex trials that [...]

    July 10, 2025
  • Clinical Trials,Patient Centricity,Precision medicine

    Phesi analysis reveals colorectal cancer has highest volume of real-world data — but oncology trials remain outdated

    A new analysis by clinical data analytics firm Phesi reveals [...]

    May 19, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Clairity raises $43 million to launch FDA-authorized AI platform for breast cancer risk prediction
    Categories: Artificial Intelligence, Biotech, Clinical Development, Diagnostics, Digital Health, Drug Development, Global health, Healthcare leadership, Precision medicine, Women's Health
  • FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML
    Categories: Drug approval, Oncology, Pharmaceuticals and therapeutics
  • Successful treatment for ALS could deliver billions in global value
    Categories: Neurosciences, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top